On May 11, 2026, six insiders at Rapport Therapeutics, Inc. (RAPP) executed sales of company stock, collectively totaling approximately $32.26 million. The transactions involved the sale of 133,618 shares each at a price of $40.24 per share.
The selling entities included Rock Ventures V, L.P. Third, Rock Ventures Vi, L.P. Third, Rock Ventures Gp V, Lp Third, Rock Ventures Gp Vi, L.P. Third, Gp Vi, Llc Trv, and Gp V, Llc Trv. These sales represent significant dispositions of shares by entities associated with the company's leadership.
While insider sales can be motivated by various factors such as portfolio diversification or tax planning, a coordinated sale by multiple insiders can sometimes draw investor attention. No additional context was provided regarding the specific reasons behind these transactions.